Redcare Pharmacy N.V. Redcare Pharmacy raises again full-year 2026 revenue guidance driven by strong Rx momentum in Germany

Redcare Pharmacy raises again full-year 2026 revenue guidance driven by strong Rx momentum in Germany

Sevenum, the Netherlands, September 28, 2026. Redcare Pharmacy N.V. announces that it is raising its full-year 2026 guidance for the second time this year, driven by continued strong Rx revenue momentum in Germany.

The Company now expects: 

• Total revenue growth of 16% to 18% (previously: 15% to 17%)
• Non-Rx growth of 10% to 12% (unchanged)
• Rx revenue in Germany between EUR 730 and 760 million, representing growth of 45% to 51% (previously: EUR 680 to 720 million, representing growth of 35% to 43%)
• Adjusted EBITDA margin between 2.5% and 3.0% (unchanged)

Contact:
Irina Zhurba 
Investor Relations Redcare Pharmacy